journal article·2021-09-28Open access

Comparison of Palliative Care Models in Idiopathic Pulmonary Fibrosis

Sarah Younus, Jeffrey A. Bakal, Janice Richman-Eisenstat, Ghadah Alrehaili, Sharina Aldhaheri, Michelle Morales, Naomi Rippon, Elisabeth Bendstrup, Ingrid Harle, Onofre Moran-Mendoza, Shaney L. Barratt, Huzaifa Adamali, Meena Kalluri

Applied Sciences· Volume 11· Issue 19

Abstract

Introduction: Palliative care (PC) is recommended in idiopathic pulmonary fibrosis (IPF) patients but poorly implemented. Integration of PC into routine management by pulmonologists may improve overall and end-of-life (EOL) care, but the optimal model of PC delivery is unknown. Objective: To describe three PC care delivery models and their impact on EOL; the Multidisciplinary Collaborative ILD clinic, Edmonton, Canada (EC) and the Bristol ILD Service, UK (BC) that provide primary level PC; and the Queen’s University ILD Clinic, Kingston, Canada (QC), which refers IPF patients to a specialist PC Clinic using specific referral criteria. Methods: A multicenter retrospective observational study of IPF patients receiving care in the identified clinics (2012–2018) was designed. Demographics; PC delivery, including symptom management; advance care planning (ACP); and location of death data were examined. Results: 298 IPF patients were included (EC 95, BC 84, and QC 119). Median age was 71 years with 74% males. Overall, 63% (188) patients received PC. Primary PC approach in EC and BC led to more patients receiving PC (98% EC, 94% BC and 13% QC (p < 0.001/<0.001)) with earlier initiation compared to QC. Associated higher rates of non-pharmacologic dyspnea management [98% EC, 94% BC, and 2% QC (p < 0.001/<0.001); opioids (45% EC and BC, and 23% QC (p < 0.001/<0.001)); and ACP (100% EC and BC, and 13% QC patients (p < 0.001/<0.001))] were observed. Median follow up (IQR) was 16 months (5–28) with 122 deaths (41%). Primary PC model in EC and BC decedents was associated with more PC delivery (91% EC, 92% BC and 19% QC (p < 0.001)) with more symptoms management, oxygen, and opiate use than QC (p < 0.001; p = 0.04; p = 0.01). EOL discussions occurred in 73% EC, 63% BC, and 4% QC decedents (p = 0.001). Fifty-nine% (57) died at home or hospice and 38% (36) in hospitals. Concordance rate between preferred and actual location of death was 58% in EC (0.29 (−0.02–0.51)) and 37% in BC models (−0.11 (−0.20–0.15)). Conclusions: Primary PC approach for IPF is feasible in ILD clinics with concurrent disease management and can improve access to symptom management, ACP, PC and EOL care. Reliance on PC specialist referral for PC initiation outside of the ILD clinic can result in delayed care.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Chronic Obstructive Pulmonary Disease (COPD) Research · Dysphagia Assessment and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada

Provincial Research Data Services, Alberta Health Services, Edmonton, AB T6G 2C8, Canada

Alberta Health Services, Edmonton, AB T6G 1Z1, Canada

Division of Respirology and Sleep Medicine, Department of Medicine, Queen’s University, Kingston, ON K7L 2V6, Canada

Bristol Interstitial Lung Disease, North Bristol Trust, Southmead Hospital, Bristol BS10 5NB, UK

Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200 Aarhus, Denmark

Division of Palliative Care, Department of Medicine, Queen’s University, Kingston, ON K7L 3J7, Canada

References (38)

Show source-provided references
1. Health-related quality of life in patients with idiopathic pulmonary fibrosis: A systematic review10.1136/thx.2004.035220 ↗
2. The supportive care needs of people living with pulmonary fibrosis and their caregivers: A systematic review10.1183/16000617.0125-2019 ↗
3. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry10.1111/resp.12989 ↗
4. Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life10.1186/s12890-018-0738-x ↗
5. Palliative care in interstitial lung disease: Living well10.1016/S2213-2600(17)30383-1 ↗
6. A qualitative study of unmet healthcare needs in chronic obstructive pulmonary disease: A potential role for specialist palliative care?10.1513/AnnalsATS.201404-155BC ↗
7. The palliative care needs for fibrotic interstitial lung disease: A qualitative study of patients, informal caregivers and health professionals10.1177/0269216313497226 ↗
8. Health care costs at the end of life for patients with idiopathic pulmonary fibrosis. Evaluation of a pilot multidisciplinary collaborative interstitial lung disease clinic10.1513/AnnalsATS.201909-707OC ↗
9. Palliative care for patients with advanced fibrotic lung disease: A randomised controlled phase II and feasibility trial of a community case conference intervention10.1136/thoraxjnl-2014-206583 ↗
10. Palliative care for people with non-malignant lung disease: Summary of current evidence and future direction10.1177/0269216313493467 ↗
11. An official American Thoracic Society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses10.1164/rccm.200605-587ST ↗
12. Generalist plus specialist palliative care—Creating a more sustainable model10.1056/NEJMp1215620 ↗
13. Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: A novel model to address palliative care needs10.1136/bmjresp-2018-000360 ↗
14. Comprehensive supportive care for patients with fibrosing interstitial lung disease10.1164/rccm.201903-0614PP ↗
15. Essential components of an interstitial lung disease clinic10.1016/j.chest.2020.09.256 ↗
16. Healthcare pathway and patients’ expectations in pulmonary fibrosis10.1183/23120541.00134-2016 ↗
17. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management10.1164/rccm.2009-040GL ↗
18. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis10.1378/chest.14-1127 ↗
19. Rajala, K., Lehto, J.T., Saarinen, M., Sutinen, E., Saarto, T., and Myllärniemi, M. (2016). End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat. Care, 15.10.1186/s12904-016-0158-8 ↗
20. End-of-life care in oxygen-dependent ILD compared with lung cancer: A national population-based study10.1136/thoraxjnl-2015-207439 ↗
21. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: A randomized controlled pilot study10.1186/s12931-019-1266-9 ↗
22. Referral to palliative care infrequent in patients with idiopathic pulmonary fibrosis admitted to an intensive care unit10.1089/jpm.2016.0258 ↗
23. Bischoff, K.E., Choi, S., Su, A., Cohen, E., O’Riordan, D.L., Oettel, E., Blachman, M., Meister, S., Zapata, C., and Lindenfeld, P. (2021). Better together: A mixed-methods study of palliative care co-management for patients with interstitial lung disease. J. Palliat. Med.10.1089/jpm.2020.0787 ↗
24. Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers10.1136/thoraxjnl-2020-215731 ↗
25. Brighton, L.J., Tunnard, I., Farquhar, M., Booth, S., Miller, S., Yi, D., Gao, W., Bajwah, S., Man, W.D., and Reilly, C. (2018). Recommendations for services for people living with chronic breathlessness in advanced disease: Results of a transparent expert consultation. Chronic Respir. Dis., 16.10.1177/1479973118816448 ↗
26. Breathlessness services as a new model of support for patients with respiratory disease10.1177/1479972317721557 ↗
27. Specialist palliative care is more than drugs: A retrospective study of ILD patients10.1007/s00408-011-9355-7 ↗
28. The breathing, thinking, functioning clinical model: A proposal to facilitate evidence-based breathlessness management in chronic respiratory disease10.1038/s41533-017-0024-z ↗
29. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis10.1056/NEJMoa1402582 ↗
30. The European MultiPartner IPF Registry (EMPIRE): Validating long-term prognostic factors in idiopathic pulmonary fibrosis10.1186/s12931-019-1271-z ↗
31. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): A prospective, open-label, mixed-method, crossover randomised controlled trial10.1016/S2213-2600(18)30289-3 ↗
32. What patients with idiopathic pulmonary fibrosis and caregivers want: Filling the gaps with patient reported outcomes and experience measures10.1016/j.amjmed.2019.08.032 ↗
33. Early integrated palliative care bundle impacts location of death in interstitial lung disease: A pilot retrospective study10.1177/1049909120924995 ↗
34. Early integrated palliative approach for idiopathic pulmonary fi-brosis: A narrative study of bereaved caregivers’ experiences10.1177/0269216318789025 ↗
35. Kalluri, M., Orenstein, S., Archibald, N., and Pooler, C. (2021). Advance Care Planning Needs in Idiopathic Pulmonary Fi-brosis: A Qualitative Study. Am. J. Hosp. Palliat. Med.10.1177/10499091211041724 ↗
36. Palliative care for idiopathic pulmonary fibrosis patients: Pulmonary physicians’ view10.1016/j.jpainsymman.2020.06.012 ↗
37. Preference for palliative care in cancer patients: Are men and women alike?10.1016/j.jpainsymman.2018.03.014 ↗
38. Kalafatis, D., Gao, J., Pesonen, I., Carlson, L., Sköld, C.M., and Ferrara, G. (2019). Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden. BMC Pulm. Med., 19.10.1186/s12890-019-0994-4 ↗